Cytokinetics, Incorporated (CYTK) Stock: Price, Forecast & Analyst Target
Cytokinetics, Incorporated (CYTK) — MoonshotScore 12/100 (Weak band), calculated Nov 18, 2026. Price $51.46 (+0.27%), as of the Nov 19, 2026 trading session; market cap $7.17B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 6.35× (cash as of Sep 30, 2026) · expected results Feb 23, 2027
Cytokinetics, Incorporated · CYTK · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Cytokinetics develops medicines that alter muscle contractility and now markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy. Its valuation hinges on whether MYQORZO demand and international aficamten launches can outrun a heavy research and commercial cost base before ongoing cash use narrows its financial flexibility.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cytokinetics (CYTK)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a strained balance sheet, weak growth and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.
- EPS beat 5 of the last 8 reports
- Altman Z -1.79 · Piotroski F 2
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 12 | Weak | |
| 12 | Weak | |
| 12 | Weak | |
| 12 | Weak | |
| 12 | Weak | |
| 12 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $51.46 | |
| Change on the day | +0.27% | |
| 52-week range | $51.38–$88.31 | |
| Market capitalisation | $7.17B | — |
| Price / earnings (trailing) | -17.39 | |
| Shares traded on the day | 1.74M | |
| Beta (volatility vs the S&P 500) | 0.36 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect to launch in the U.K. this quarter and in additional countries in 2027.
Robert I. Blum · Statement from
We also recently received approval in Canada, and we expect to launch in the U.K. this quarter and in additional countries in 2027.
Andrew Callos · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Cytokinetics (CYTK): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cytokinetics (CYTK), and what does it report?
Short answer · as of
Cytokinetics sells and develops muscle activators and inhibitors, with demand ultimately tied to treatment adoption among eligible cardiac and skeletal-muscle patients.
Research dated 2026-09-13.
MYQORZO provides a marketed product, while aficamten, omecamtiv mecarbil, Ulacamten and the skeletal-muscle program extend the same contractility-focused research platform across different diseases.
Reported revenue is not yet a clean proxy for MYQORZO prescription demand. The annual segment disclosure identifies collaboration revenue, quarterly revenue has swung sharply, and the income statement still reflects a research-intensive company carrying a substantial commercial cost base.
What do the latest results show for Cytokinetics (CYTK)?
Research dated 2026-09-13.
Revenue and gross profit rose from the preceding period, while operating and net losses narrowed. Reported earnings history also shows revenue ahead of consensus and a less negative loss per share than expected, but operating cash use deepened and selling and administrative expense remained above research spending.
Collaboration economics can make quarterly revenue uneven, so the latest increase does not by itself establish a stable MYQORZO demand curve. Management is directing attention toward the United Kingdom launch and a country-by-country aficamten rollout governed by local health-technology assessment processes.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $47.56M Sep 30, 2026
- Latest quarter · R&D
- $99.28M Sep 30, 2026
- Latest quarter · SG&A
- $113.14M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$167.09M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $47.56M | $99.28M | $113.14M | −$167.09M |
| Jun 30, 2026 | $28.62M | $97.81M | $104.40M | −$179.17M |
| Mar 31, 2026 | $19.36M | $95.53M | $104.90M | −$183.62M |
| Dec 31, 2025 | $17.75M | $101.54M | $91.72M | −$178.37M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $47.56M Nov 4, 2026
- Latest report · revenue estimate
- $41.88M Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $47.56M | $41.88M | −$1.3700 | −$1.4300 |
| Aug 6, 2026 | $28.62M | $17.59M | −$1.5000 | −$1.6300 |
| May 5, 2026 | $19.36M | $8.52M | −$1.6700 | −$1.6700 |
| Feb 24, 2026 | $17.75M | $6.93M | −$1.5000 | −$1.4800 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2M | -$306M | -$2.55 (diluted) |
| Q4 FY2025 | $18M | -$183M | -$1.50 (diluted) |
| Q1 FY2026 | $19M | -$206M | -$1.67 (diluted) |
| Q2 FY2026 | $29M | -$199M | -$1.50 (diluted) |
What are the financial strengths and risks for Cytokinetics (CYTK)?
Short answer
Cash and short-term investments were $1.13B at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$124.02M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments rose sharply in the latest period, and adding long-term investments puts total liquidity above debt. Cash and short-term investments alone remain below debt, however, while operations continue to consume cash and the computed runway is finite.
The specific financial risk is a slow commercial ramp meeting persistent research and selling costs. Consensus still anticipates losses before profitability emerges, trailing margins remain deeply negative, and the distress and quality screens are weak; continued revenue volatility or heavier launch spending would accelerate pressure on liquidity.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.79 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$124.02M Sep 30, 2026
- Previous quarter · operating cash flow
- −$159.84M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$124.02M | −$700,000 |
| Jun 30, 2026 | −$159.84M | −$4.33M |
| Mar 31, 2026 | −$145.46M | −$5.93M |
| Dec 31, 2025 | −$142.65M | −$5.64M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Cytokinetics (CYTK)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13.
At the scheduled earnings update, watch whether revenue keeps advancing without another collaboration-driven reversal, whether gross profit remains positive, and whether operating losses and cash use begin to moderate. Commercial leverage would appear as revenue growing faster than selling and administrative expense rather than spending merely shifting from research toward launch activity.
Execution abroad offers a separate test. Management expects United Kingdom drug supply and full launch later in the year, sees a potential Canadian approval, and plans further launches as national assessment processes are completed; progress against that sequence would demonstrate whether aficamten can become a geographically broader commercial franchise.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect to launch MYQORZO in the U.K. in this quarter and complete enrollment in Cohort 1 of AMBER-HFpEF.
Robert I. Blum ·
And in early 2027, we expect to submit our application relating to the results of ACACIA-HCM in the EU and launch in additional countries in 2027 as well as share top line results from the adolescent cohort of CEDAR-HCM.
Robert I. Blum ·
How does Cytokinetics compare with its peers?
Short answer
Cytokinetics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Cytokinetics is no longer simply a research-stage biotechnology company because MYQORZO is marketed and commercial spending is already prominent. Yet its economics still resemble a development-heavy business: revenue is uneven, losses are substantial, cash use is persistent and future profitability depends on a steep commercial expansion.
Its scientific distinction is a portfolio built around adjusting muscle contractility in different directions. Cardiac myosin inhibitors target hypercontractility, omecamtiv mecarbil is intended to address heart failure with severely reduced pumping function, and the skeletal-muscle program activates troponin rather than extending a conventional cardiology portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| Cytokinetics (CYTK) — this page | $51.46 | $7.17B | 12 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $81.00 – $118.00
- Consensus target
- $107.14
- Median target
- $112.00
Consensus record · Captured .
Measured against a quoted price of $51.46 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 9, 2026
- Transactions
- 100
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 28
- Other transactions
- 72
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 491 Period end Sep 30, 2026
- Previous quarter · holders
- 515 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 21,041,152 |
| T. Rowe Price Investment Management, INC. | 18,912,704 |
| Wellington Management Group Llp | 10,590,381 |
| Polar Capital Holdings PLC | 9,635,314 |
| State Street Corp | 7,143,229 |
Tracked investors
Which of the 16 named investors we follow held CYTK in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CYTK in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cytokinetics (CYTK)?
- Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
- Cytokinetics Announces Inducement Stock Grants for New Employees
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics Announces FDA Approval of Supplemental New Drug Application for MYQORZO® (aficamten)
What Investors Ask About Cytokinetics (CYTK) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does MYQORZO change Cytokinetics’ business model?
MYQORZO gives Cytokinetics a marketed therapy for symptomatic obstructive hypertrophic cardiomyopathy, adding product commercialization to collaboration economics and pipeline development. The financial statements have not yet settled into a stable product-led revenue pattern.
Why is aficamten’s international rollout staggered?
Management says launches depend on health-technology assessment processes within each country. The United Kingdom is expected to lead the next wave, with additional markets following as their local processes conclude.
Can Cytokinetics fund the MYQORZO and aficamten rollout from current liquidity?
Current cash and investments provide meaningful runway and exceed total debt when long-term investments are included. Persistent operating cash use, elevated launch spending and a cash balance below debt on the narrower liquidity basis mean financing risk has not disappeared.
What could Ulacamten add to Cytokinetics’ muscle platform?
Ulacamten extends the cardiac myosin inhibitor approach toward heart failure associated with excessive contractility rather than the marketed obstructive hypertrophic cardiomyopathy indication. It broadens the scientific opportunity while adding another clinical program to an already costly research portfolio.
What is the CYTK stock price today?
The last price recorded for Cytokinetics, Incorporated (CYTK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CYTK price target?
The analyst consensus price target for Cytokinetics, Incorporated (CYTK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 78 figures on this page — 2 from SEC filings and earnings calls, 69 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold CYTK
Funds in our ETF coverage that list CYTK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.30% |